SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences
- PMID: 12843218
SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences
Abstract
The purpose of this study was to measure how (18)F-FDG PET standardized uptake values (SUVs) change over time in breast cancer and to examine the feasibility of a method to adjust for modest variations in the time of uptake measurement experienced in clinical practice.
Methods: (18)F-FDG PET was performed as 60-min dynamic imaging with an additional image acquired at approximately 75 min after injection. For 20 newly diagnosed, untreated, locally advanced breast cancer patients, both the maximum SUV and the average SUV within the lesion were calculated with and without correction for blood glucose concentration. A linear regression analysis of the portion of the time-activity curves starting at 27 min after injection was used to estimate the rate of SUV change per minute during the interval from 27 to 75 min. The rate of SUV change with time was compared with the instantaneous SUV obtained at different times from 27 to 75 min.
Results: In untreated breast cancer, (18)F-FDG SUV values changed approximately linearly after 27 min at a rate ranging from -0.02 to 0.15 per minute. In addition, the rate of SUV change was linearly correlated with the instantaneous SUV measured at different times after injection (r(2) ranged from 0.82 to 0.94; P < 0.001). Using this information, an empirical linear model of SUV variation with time from injection to uptake measurement was formulated. The comparison method was then applied prospectively to a second set of 20 locally advanced breast cancer lesions not included in the initial analysis. The average percent error using the method to adjust for time differences was 8% and 5% for maximum SUVs and average SUVs ranging from 2 to 12.
Conclusion: In untreated breast cancer, the SUV at any time point approximately predicts the rate of change of SUV over time. A comparison method based on this finding appears feasible and may improve the usefulness of the SUV by providing a means of comparing SUV acquired at different times after injection.
Similar articles
-
Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.J Nucl Med. 2016 Feb;57(2):226-30. doi: 10.2967/jnumed.115.162289. Epub 2015 Oct 22. J Nucl Med. 2016. PMID: 26493206 Free PMC article.
-
Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.Eur J Nucl Med Mol Imaging. 2003 May;30(5):674-81. doi: 10.1007/s00259-003-1127-z. Epub 2003 Mar 15. Eur J Nucl Med Mol Imaging. 2003. PMID: 12640556 Clinical Trial.
-
Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.Eur J Radiol. 2009 Jun;70(3):530-8. doi: 10.1016/j.ejrad.2008.01.045. Epub 2008 Apr 18. Eur J Radiol. 2009. PMID: 18395387
-
Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.Med Phys. 2015 Jul;42(7):3801-13. doi: 10.1118/1.4921363. Med Phys. 2015. PMID: 26133582 Free PMC article.
-
[Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in gynecological neoplasms].Bull Cancer. 2003 Feb;90 Spec No:S47-55. Bull Cancer. 2003. PMID: 12739336 Review. French. No abstract available.
Cited by
-
Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?J Nucl Med. 2024 Sep 3;65(9):1349-1356. doi: 10.2967/jnumed.123.266469. J Nucl Med. 2024. PMID: 39142828 Free PMC article.
-
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):642-50. doi: 10.1007/s00259-010-1665-0. Epub 2011 Jan 5. Eur J Nucl Med Mol Imaging. 2011. PMID: 21207024 Clinical Trial.
-
Use of count-based image reconstruction to evaluate the variability and repeatability of measured standardised uptake values.PLoS One. 2018 Feb 12;13(2):e0192549. doi: 10.1371/journal.pone.0192549. eCollection 2018. PLoS One. 2018. PMID: 29432459 Free PMC article.
-
Quantitative PET Imaging and Clinical Parameters as Predictive Factors for Patients With Cervical Carcinoma: Implications of a Prediction Model Generated Using Multi-Objective Support Vector Machine Learning.Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983804. doi: 10.1177/1533033820983804. Technol Cancer Res Treat. 2020. PMID: 33357081 Free PMC article.
-
A review on segmentation of positron emission tomography images.Comput Biol Med. 2014 Jul;50:76-96. doi: 10.1016/j.compbiomed.2014.04.014. Epub 2014 Apr 28. Comput Biol Med. 2014. PMID: 24845019 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical